On May 9th, GaBI Journal published a whitepaper titled “Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars”, based on the recent survey of 41 Canadian ophthalmologists by ASBM and the International Federation on Ageing (IFA). The paper is authored by IFA Secretary-General Jane Barratt and ASBM Executive Director Michael Reilly. The survey revealed that 81% were not […]
On April 30th, the Generics and Biosimilar Initiative (GaBI) published a meeting report on a 2-hour webinar entitled “Non-Medical Switching of Biologicals and Biosimilars: Canada, Europe, and the US”, hosted July 20th, 2022 by ASBM and GaBI. During the webinar, academic clinicians, patient advocates, policymakers and regulatory experts from Canada and the US shared their experience and […]
By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. Under this plan – authorized by the Inflation Reduction Act (IRA) signed in to law last year – Medicare will “negotiate” (set) maximum […]
